First Time Loading...

Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 982.29 USD 1.48% Market Closed
Updated: May 18, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Balance Sheet

34.4B
+4%
Assets
Growth Rates:
1 Year
+14%
3 Years
+93%
5 Years
+167%
7 Years
+340%
10 Years
+954%
7.4B
+4%
Liabilities
Growth Rates:
1 Year
+12%
3 Years
+27%
5 Years
+116%
7 Years
+150%
10 Years
+603%
27B
+4%
Equity
Growth Rates:
1 Year
+15%
3 Years
+125%
5 Years
+186%
7 Years
+455%
10 Years
+1 121%

Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc

34.4B
Assets
7.4B
Liabilities
34.4B
Assets
7.4B
Liabilities
Current Assets 18.9B
Cash & Short-Term Investments 10.5B
Receivables 5.2B
Other Current Assets 3.1B
Non-Current Assets 15.5B
Long-Term Investments 7B
PP&E 4.2B
Intangibles 1.1B
Other Non-Current Assets 3.2B
Current Liabilities 3.6B
Accounts Payable 671.3m
Accrued Liabilities 2.4B
Other Current Liabilities 516.7m
Non-Current Liabilities 3.8B
Long-Term Debt 2.7B
Other Non-Current Liabilities 1.1B

Balance Sheet
Regeneron Pharmaceuticals Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
649
809
535
813
1 468
1 618
2 194
2 886
3 106
16 241
Cash Equivalents
649
809
535
813
1 468
1 618
2 194
2 886
3 106
16 241
Short-Term Investments
252
236
503
597
1 342
1 597
1 393
2 809
4 636
8 115
Total Receivables
976
1 468
1 612
1 974
2 243
2 672
4 115
6 037
5 329
5 667
Accounts Receivables
976
1 468
1 612
1 974
2 243
2 672
4 115
6 037
5 329
5 667
Other Receivables
0
0
0
0
0
0
0
0
0
0
Inventory
129
239
399
726
1 151
1 416
1 917
1 951
2 402
2 581
Other Current Assets
125
164
131
225
243
387
161
332
411
387
Total Current Assets
2 131
2 915
3 180
4 335
6 448
7 689
9 779
14 015
15 884
19 479
PP&E Net
974
1 594
2 083
2 359
2 576
2 890
3 222
3 482
3 763
4 224
PP&E Gross
0
1 594
2 083
2 359
2 576
2 890
3 222
3 482
3 763
4 224
Accumulated Depreciation
0
331
426
566
729
922
1 131
1 398
1 669
1 979
Intangible Assets
0
0
0
0
0
0
0
0
916
1 039
Long-Term Investments
460
632
864
1 486
1 801
3 312
3 195
6 878
6 640
5 471
Other Long-Term Assets
272
468
846
584
911
913
968
1 060
2 012
2 867
Total Assets
3 838
N/A
5 609
+46%
6 973
+24%
8 764
+26%
11 735
+34%
14 805
+26%
17 163
+16%
25 435
+48%
29 215
+15%
33 080
+13%
Liabilities
Accounts Payable
100
141
135
178
218
418
476
564
589
4 425
Accrued Liabilities
384
503
508
637
751
1 037
1 502
1 881
2 074
2 358
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
127
0
0
0
0
720
0
0
Other Current Liabilities
171
167
471
321
473
641
720
768
478
459
Total Current Liabilities
655
811
1 241
1 135
1 443
2 097
2 697
3 933
3 141
3 423
Long-Term Debt
458
363
352
703
709
714
2 696
1 980
2 701
2 703
Other Liabilities
175
780
931
781
826
905
745
754
708
981
Total Liabilities
1 287
N/A
1 954
+52%
2 524
+29%
2 620
+4%
2 977
+14%
3 716
+25%
6 138
+65%
6 666
+9%
6 551
-2%
7 107
+8%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
Retained Earnings
217
853
1 748
2 947
5 254
7 380
10 893
18 968
23 307
27 260
Additional Paid In Capital
2 451
3 100
3 030
3 513
3 912
4 429
6 716
8 088
9 949
11 354
Treasury Stock
170
306
316
316
396
740
6 613
8 261
10 353
12 560
Other Equity
52
9
13
1
12
21
29
26
239
81
Total Equity
2 550
N/A
3 655
+43%
4 449
+22%
6 144
+38%
8 757
+43%
11 090
+27%
11 025
-1%
18 769
+70%
22 664
+21%
25 973
+15%
Total Liabilities & Equity
3 838
N/A
5 609
+46%
6 973
+24%
8 764
+26%
11 735
+34%
14 805
+26%
17 163
+16%
25 435
+48%
29 215
+15%
33 080
+13%
Shares Outstanding
Common Shares Outstanding
102
105
106
108
109
110
107
109
110
109

See Also

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall Street Estimates
REGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.